ANIX
Anixa Biosciences, Inc.NASDAQHealthcare$2.55+1.57%ClosedMarket Cap: $85.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.71
P/S
0.00
EV/EBITDA
-7.75
DCF Value
$0.03
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.6%
ROA
-67.7%
ROIC
-78.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $0.00 | -Infinity% | $-2.7M | $-2.6M | $-0.08 | — |
| Q4 2025 | $0.00 | -Infinity% | $-2.9M | $-2.7M | $-0.08 | — |
| FY 2025 | $0.00 | -Infinity% | $-11.7M | $-10.9M | $-0.34 | — |
| Q3 2025 | $0.00 | NaN% | $-2.4M | $-2.3M | $-0.07 | — |
| Q2 2025 | $0.00 | NaN% | $-3.0M | $-2.8M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-3.4M | $-3.2M | $-0.10 | — |
| Q4 2024 | $0.00 | NaN% | $-3.2M | $-2.9M | $0.30 | — |
| FY 2024 | $0.00 | NaN% | $-13.8M | $-12.6M | $-0.39 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.3M | $-0.10 | — |
| Q2 2024 | $0.00 | NaN% | $-3.6M | $-3.3M | $-0.10 | — |
| Q1 2024 | $0.00 | NaN% | $-3.6M | $-3.3M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-3.1M | $-2.7M | $-0.09 | — |